NEXT Life Sciences has conducted a successful clinical trial of the delivery system for Plan A™, developed as the first non-hormonal, long-acting, and on-demand reversible birth control for men. This is an essential step toward finally meeting demand for a male contraception option other than condoms, vasectomy, and withdrawal.
An affordable and accessible male contraceptive option
Plan A utilizes a hydrogel called Vasalgel that’s designed to prevent sperm from traveling through the vas deferens (sperm duct). The Parsemus Foundation initially developed Vasalgel, completing important chemical and preclinical studies. In 2022, the foundation partnered with NEXT Life Sciences to bring Vasalgel to market. The partnership has been highly successful with an aligned mission to offer a new male contraceptive that’s affordable and accessible.
“Knowing that many women do not tolerate hormone-based pills or contraception devices, the addition of Plan A to the market gives everyone a wider array of contraception options,” said Dr. Darlene Walley, Chief Executive Officer of NEXT Life Sciences. “Plan A allows men to participate in family planning by allowing them to basically ‘set and forget’ their contraceptive option.”
The importance of the Plan A delivery system
NEXT has the expertise, experienced staff, and resources needed to move Plan A forward. Numerous steps along the pathway to bringing the product to market have been completed. The recent successful trial in Canada tested a critical component of Plan A: the delivery system, or the method of inserting Vasalgel into the vas deferens.
Plan A is designed to be quickly administered by a medical professional in a variety of settings — not just clinics or hospitals. The proprietary access method was previously tested in Australia, which successfully confirmed that the hydrogel can be held in place while also being less invasive than traditional methods, such as syringes or needles. Doctors have now successfully used the new delivery method introduced by Plan A™ in procedures involving 50 men.
Successful clinical trial for new technology
According to NEXT Life Sciences, the Plan A™ delivery device has now:
- Been used successfully by physicians across two continents with ease, regardless of prior experience levels.
- Proven it can be used under FDA-compliant standards, reinforcing our confidence in U.S. regulatory alignment.
- Been praised by physicians and urologists involved in the study as minimally invasive and highly intuitive to use, giving them strong confidence in Plan A™.
“The Vasectomie Quebec medical and nursing team is very proud to collaborate with NEXT Life Sciences toward the development of Plan A,” said Dr. Michel Labrecque, one of the five participating physicians in the Canadian clinical trial who has performed 40,000 vasectomies throughout his career. “We look forward to when this option becomes commercially available so we can offer it to our patients.”
To hear about the latest news on Vasalgel and Plan A, be sure to sign up for updates.
Physicians from Canada and Australia have tested the Plan A™ male birth control delivery system with 100% success in 50 men.
